Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lung Cancer Pathology Pattern Predicts Recurrence

By LabMedica International staff writers
Posted on 21 Aug 2013
A specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

The pattern will help surgeons identify which patients are more likely to benefit from less radical lung-sparing surgery, and which patients will benefit from more extensive surgery.

Pathologists at the Memorial Sloan-Kettering Cancer Center (New York, NY, USA) evaluated the clinical characteristics and pathology information of 734 patients who had surgery for early-stage adenocarcinoma, the most common subtype of non-small-cell lung cancer. The scientists evaluated the prognostic utility of a classification, called micropapillary (MIP) morphology, for patients with small, early-stage lung adenocarcinomas.

All available hematoxylin and eosin-stained slides were reviewed by two pathologists. A minimum of two hematoxylin and eosin stained slides were reviewed per patient; the median was four; and ranged from 2 to 10 slides/patient. Each tumor was evaluated by comprehensive histologic subtyping, and the percentage of each histologic component was recorded in 5% increments. They found that tumors in 40% of those patients exhibited an abnormal MIP cell pattern strongly associated with cancer recurrence after surgery.

The findings suggest that limited resection may not be appropriate for patients with the MIP pattern, as they were found to have a 34% risk of the cancer returning within five years after lung-sparing surgery, or limited resection, in which the tumor is removed by minimally invasive means and lung function is preserved. In contrast, patients with the MIP pattern who underwent lobectomy, the standard approach in which up to a third of the lung is removed along with the tumor, had only a 12% incidence of recurrence over a five-year period.

The scientists at Memorial Sloan-Kettering are working to develop new technology that can be used to precisely identify which tumors have the MIP pattern before or during surgery. This will not only help doctors recommend the most effective surgical approach for each patient, but will result in fewer patients requiring additional treatment. The study was published on August 7, 2013, in the Journal of the National Cancer Institute.

Related Links:

Memorial Sloan-Kettering Cancer Center

.




Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.